Applied DNA Sciences, Inc. (NASDAQ:APDN) Sees Significant Increase in Short Interest

Applied DNA Sciences, Inc. (NASDAQ:APDN) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 298,700 shares, a growth of 10.3% from the March 31st total of 270,800 shares. Based on an average trading volume of 150,500 shares, the short-interest ratio is presently 2.0 days.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. StockNews.com started coverage on shares of Applied DNA Sciences in a report on Monday. They set a “hold” rating on the stock. HC Wainwright dropped their price target on Applied DNA Sciences from $40.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, February 9th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Applied DNA Sciences stock. AMH Equity Ltd boosted its position in Applied DNA Sciences, Inc. (NASDAQ:APDN) by 76.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 587,232 shares of the technology company’s stock after purchasing an additional 254,232 shares during the quarter. Applied DNA Sciences comprises about 0.9% of AMH Equity Ltd’s portfolio, making the stock its 18th biggest holding. AMH Equity Ltd owned approximately 4.30% of Applied DNA Sciences worth $711,000 at the end of the most recent reporting period. 22.22% of the stock is currently owned by institutional investors and hedge funds.

Applied DNA Sciences Stock Performance

NASDAQ APDN opened at $4.03 on Thursday. Applied DNA Sciences has a 52 week low of $3.60 and a 52 week high of $37.20. The stock’s 50 day moving average price is $8.60 and its two-hundred day moving average price is $12.57. The stock has a market capitalization of $3.43 million, a price-to-earnings ratio of -0.37 and a beta of 0.07.

Applied DNA Sciences (NASDAQ:APDN) last issued its quarterly earnings results on Thursday, February 8th. The technology company reported ($1.80) EPS for the quarter, beating the consensus estimate of ($6.20) by $4.40. The firm had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $0.70 million. Applied DNA Sciences had a negative return on equity of 159.93% and a negative net margin of 80.14%. On average, equities research analysts forecast that Applied DNA Sciences will post -12.6 EPS for the current year.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.